Evidence map›Paper›PMID 32232211›Full record

ReviewNorthern clinics of Istanbul2020

Tumor suppressor and oncogenic role of long non-coding RNAs in cancer.

Esra Guzel, Tugba Muhlise Okyay, Burhanettin Yalcinkaya, Seymanur Karacaoglu, Melek Gocmen, Muhammed Huseyin Akcakuyu

Abstract readReview
In one paragraph

Review in Northern clinics of Istanbul, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. The role of exosomal long non-coding RNAs in head, neck and thyroid cancers.Medical oncology (Northwood, London, England) · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Transcriptional rewiring in cancer driven byFrontiers in pharmacology · 2025
    Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esra GuzelDepartment of Molecular Biology and Genetics, Health Sciences University, Hamidiye Institute of Health Sciences, Istanbul, Turkey.
Tugba Muhlise OkyayDepartment of Medical Biochemistry, Health Sciences University, Hamidiye Faculty of Medicine, Istanbul, Turkey.
Burhanettin YalcinkayaTUBITAK National Metrology Institute (UME), Kocaeli, Turkey.
Seymanur KaracaogluHealth Sciences University, Hamidiye Faculty of Medicine, Istanbul, Turkey.
Melek GocmenHealth Sciences University, Hamidiye Faculty of Medicine, Istanbul, Turkey.
Muhammed Huseyin AkcakuyuHealth Sciences University, Hamidiye Faculty of Medicine, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-coding RNAs are RNA molecules that are not translated into the protein, making up the vast majority of the human genome. Long non-coding RNAs (lncRNA) are in the RNA group that has longer than 200 nucleotides, and non-protein coding transcripts. In recent years, the potential has attracted considerable attention as new important biological regulators. LncRNAs play a critical role in regulating the activity and localization of proteins, processing the production of small RNAs, and processing other RNAs. They are also involved in cell differentiation, cell cycle, proliferation, apoptosis, migration and invasion by modulation of gene expression. Abnormal expression of LncRNAs has an important role in the function of oncogenes and tumor suppressor genes. Recently, there has been an increasing number of studies on the tumorigenic effects of specific lncRNAs in the initiation and progression of cancer. In this review, general information about lncRNAs is provided, including the biological importance of lncRNAs in cancer diseases and their potential development in therapeutic applications.

Indexed as

Cancerlong noncoding RNAoncogenetumor suppressor

Identifiers

PMID32232211
PMCPMC7103751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.